drugset / Trial / NCT00143351

Mozart Relapse Study

NCT00143351

Phase 3 Completed 75 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of oral Ziprasidone

Timeline

Start
2003-06
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule Oral

Indications